Conclusion. Our findings show that miR-760 inhibits CD8+ T cell responses in LC through regulating IDO1, laying the groundwork for the development of novel vaccination therapies for the treatment of LC. The gene discussed is CD8A; the disease is laryngotracheoesophageal cleft.